IP Library Granted Patent US 8,933,076
Granted Patent B2
US 8,933,076 · App. 13/491,986 · Granted Jan 13, 2015

Pyridazine compounds, compositions and methods

Inventors: D. Martin Watterson (Chicago, IL); Linda Van Eldik (Chicago, IL); Jacques Haiech (Strasbourg, FR); Marcel Hibert (Eschau, FR); Jean-Jacques Bourguignon (Illkirch, FR); Anastasia Velentza (San Diego, CA); Wenhui Hu (Guangzhou, CN); Magdalena Zasadzki (Chicago, IL)
Assignees: Centre National de la Recherche Scientifique (CNRS); Northwestern University; Universite de Strasbourg
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,933,076
App. No.
13/491,986
Granted
Jan 13, 2015
Kind
B2
Abstract

The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for, research, drug screening, and therapeutic applications.

Claims (17)

1. A method for reducing neuroinflammation to treat a disease or condition which presents neuroinflammation in a subject comprising administering to the subject a compound of the formula Ib:

wherein:

R 1 is a piperazinyl radical which is substituted with a pyrimidinyl or pyridinyl radical;

R 2 and R 3 are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkenylene, alkoxy, alkenloxy, cycloalkyl, cycloalkenyl, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocylic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylalkyl, silythio, ═O, ═S, carboxyl, carbonyl, carbamoyl, or carboxamide and

R 4 , R 5 and R 6 are independently hydrogen, alkyl, alkoxy, halo or nitro; or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 comprising administering to the subject a compound of the Formula II:

wherein R 10 and R 11 are independently hydrogen, hydroxyl, alkyi, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, aikenyloxy, cycloalkyl, cycloalkenyl, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfinyl, sulfenyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, ureido, cyano, halo, silyl, silyloxy, silylaikyl, silylthio, ═O, ═S, carboxyl, carbonyl, carbamoyl, or carboxamide; or a pharmaceutically acceptable salt thereof.

3. A method according to claim 2 wherein the compound of Formula II is:

4. The method of claim 1 , wherein progression of said disease or condition is ameliorated or progresses to a less severe stage.

5. The method of claim 1 , wherein said compound reduces neuroinflammation associated with any one of traumatic brain injury, intracerebral hemorrhage, or Alzheimer's disease.

6. The method of claim 1 , wherein said compound decreases neuroinflammation by acting on one or more of cell signaling molecule production, activation of glia or glial activation pathways and responses, proinflammatory cytokines or chemokines, oxidative stress-related responses, acute phase proteins, components of the complement cascade, protein kinase activity, cell damage and cell death signal transduction pathways.

7. The method of claim 1 , wherein said disease includes mild cognitive impairment (MCI).

8. The method of claim 1 , further comprising: administering a pharmaceutically acceptable carrier, excipient, or vehicle to said subject and wherein kinase activity, glial activation, neuronal cell damage, and/or neuronal cell death is reduced or inhibited.

9. The method of claim 8 , wherein the progression of said disease is delayed.

10. The method of claim 1 , wherein the disease or condition treated is Alzheimer's disease, intracerebral hemorrhage or traumatic brain injury, which disease or condition presents neuroinflammation.

11. The method of claim 1 , wherein the compound inhibits pro-inflammatory cytokines or chemokines.

12. The method of claim 1 , wherein the compound inhibits IL-1β, TNF-α and/or S100β.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 29, 2012
From: NORTHWESTERN UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028466/0271 →
Continuity (5)
Division 11666803
Provisional Application 60624346 · Nov 2, 2004
Provisional Application 60723124 · Oct 3, 2005
Provisional Application 60723090 · Oct 3, 2005
Related Publication 20120245125A1 · Sep 27, 2012